It is believed that the pathology and etiology of rheumatoid arthritis involves abnormal presentation of self antigen(s) by APCs and activation of autoreactive T cells [1]. T lymphocytes have therefore been proposed to play a central role in the disease process [2 • ], the most powerful evidence for which is the association of the disease with certain human leukocyte antigen (HLA)-DR chains that are shared between various alleles of HLA-DR4 and HLA-DR1 [3, 4] . The rheumatoid synovial membrane is rich in major histocompatibility complex class II + APCs, and CD4 + T cells make clusters with such HLA-DR-positive cells [5] . The T cells present in the RA synovium express the activation markers HLA-DR, VLA-4 and CD69. However, it is not clear whether T cell activation occurs before entry to the tissue, during transendothelial migration, or in the synovium. APCs require signals from activated T cells for their differentiation and maturation [6] ; this subsequently enables APCs to activate newly arrived T cells in a specific or unspecific manner in the local inflammation (Fig. 1) . Activated T cells promote the disease progression by inducing the secretion of proinflammatory cytokines (in particular, tumor necrosis factor [TNF]-α) from macrophages and synovial cells in a contactdependent manner [7, 8] .
Introduction
It is believed that the pathology and etiology of rheumatoid arthritis involves abnormal presentation of self antigen(s) by APCs and activation of autoreactive T cells [1] . T lymphocytes have therefore been proposed to play a central role in the disease process [2 • ], the most powerful evidence for which is the association of the disease with certain human leukocyte antigen (HLA)-DR chains that are shared between various alleles of HLA-DR4 and HLA-DR1 [3, 4] . The rheumatoid synovial membrane is rich in major histocompatibility complex class II + APCs, and CD4 + T cells make clusters with such HLA-DR-positive cells [5] . The T cells present in the RA synovium express the activation markers HLA-DR, VLA-4 and CD69. However, it is not clear whether T cell activation occurs before entry to the tissue, during transendothelial migration, or in the synovium. APCs require signals from activated T cells for their differentiation and maturation [6] ; this subsequently enables APCs to activate newly arrived T cells in a specific or unspecific manner in the local inflammation (Fig. 1) . Activated T cells promote the disease progression by inducing the secretion of proinflammatory cytokines (in particular, tumor necrosis factor [TNF]-α) from macrophages and synovial cells in a contactdependent manner [7, 8] .
the amplification of the inflammatory response [9 •• ] . This paper reviews the costimulatory molecules and types of APCs involved in local APC-T cell interactions and their possible roles in the disease pathology.
Costimulatory molecules and T cell activation in the synovium
Initial T cell activation is dependent on T cell receptor triggering and costimulatory signaling through CD28-CD80/CD86 [10, 11] . APCs such as dendritic cells (DCs), macrophages, B cells and follicular DCs can provide both of these signals. APCs that cannot provide costimulatory signals are unable to activate naïve T cells unless a second signal is provided by accessory APCs. The costimulatory molecules CD80/CD86 are expressed at varying levels by APCs in the synovium. Expression of CD80 is generally low, while the expression of CD86 is relatively high and is expressed on several APCs including DCs, B cells and macrophages [12, 13] . It has been suggested that CD80/CD86 interactions influence the development of T helper (Th)1 and Th2 cells, where Th2 polarization is dependent on signals through the CD80 molecule [14 • ,15] . T cells in the synovium are of Th1 type, and even though the secretion of IFNγ is low, the Th1 cytokine IL-17 can be found in high levels [16, 17] . Expression of CD86 and lack of CD80 then correlates with the dominant population of Th1 cells in the synovium [16, 18] . APCs in the synovium might therefore be capable of the initial activation of T cells through the Th1 pathway by the expression of CD86 and secretion of IL-12. It has been shown in various models that blocking the CD28 signaling pathway can prevent or treat autoimmune diseases [19, 20] . Studies in MLR/lpr mice lacking CD28 suggest that CD28 is most probably a regulator in the induction of autoimmune diseases. Arthritis is abolished and autoantibody production is suppressed in these mice, but the accumulation of abnormal T cells is almost unchanged [21] .
The memory population of Th1 cells in the synovium has an increased number of CD28-negative cells [22] . Memory T cells, however, have a lower requirement for CD28 signaling compared with naïve T cells and can respond to T cell receptor signaling alone [23] . A much greater range of APCs can therefore stimulate memory T cells than that which stimulates naïve T cells. In addition, effector T cells are even less dependent on costimulatory signals and can respond to many types of APC including resting B cells and macrophages [24] . APCs in the synovium generally express low levels of CD80/86, but still might function as APCs for memory/effector T cells and maintain the inflammatory response by continuously activating synovial memory T cells.
In addition to CD28/CD86-80 costimulation, CD40-CD40L has been shown to contribute to T cell activation, both by independently costimulating T cells and, at least in part, by upregulating CD80/CD86 molecules on APCs [14 • ,25] . The CD40 pathway is particularly thought to be important for amplification of the T cell response, as blocking the CD40 signaling pathway has been shown to inhibit Th1 differentiation and maintenance of the immune response [26] . DCs, B cells and macrophages express CD40 in the synovium, and these APCs may be of particular importance for the disease pathogenesis.
DC-T cell interaction
Fully mature DCs are found in the perivascular area in close association with T cells and with B-cell follicles, and express markers associated with mature DCs, including major histocompatibility complex class II molecules, nuclear RelB, adhesion molecules and STAT 4 [5, 27] . DCs migrate from peripheral blood, probably under the influence of a chemotactic attractant to the synovial tissue [28] . DCs in the synovium receive differentiation signals from monocyte derived cytokines and through CD40L interaction with T cells. DCs are located adjacent to endothelial cells surrounding blood vessels in the synovium, implying that DCs derived from circulating precursors may have differentiated during a short time after transendothelial migration. If this is so, DCs could function as potent antigen presenting cells, either for external or local antigen(s) released by the ongoing synovial inflammation. Several cytokines are produced in RA synovium, including TNFα, IL-1 and granulocyte macrophage-colony stimulating factor, that can upregulate the ability of DCs to present antigen. The major DC differentiation signal is achieved through ligation of CD40, which triggers high levels of IL-12 secretion and upregulation of CD80, CD86 and ICAM-1 [29, 30] . T cells in the synovium express CD40L and, upon interaction with DCs, play an important role in upregulation of the antigen presenting capacity of synovial tissue DCs [31] . A high number of mature DCs are then able to polarize the T cell response into the Th1 pathway, giving the Th1 cells an irreversible phenotype [32] .
Antigen presentation by rheumatoid factor B cells and T cell interaction
B cells are another major source of APCs in the synovium. Rheumatoid factor (RF) B cells, in particular, are believed to play an important role in antigen presentation [33 •• ] . RF B cells can take up antigen-Ig immune complexes via their membrane Ig receptors, which have RF specificity and thus react with the IgG Fc part of antibody molecules. The B cells then process and present peptides from the antigen, and thus induce both T cell activation and T cell help for multiple antigens, as well as T cell help for RF secretion (Fig. 1) . High affinity RFs accumulate in the synovium and contribute to the disease pathogenesis by forming immune complexes and activation of complement [34] . Low affinity RFs are abundant in lymph nodes in healthy individuals, and high affinity RFs are deleted in mice [35, 36] . The reason for the persistence of high affinity RFs in RA patients but not in healthy individuals is not fully understood. However, in normals there are mechanisms that prevent replacement mutations which can lead to affinity maturation. Thus, the R:S ratio in the CDR regions are found to be extrememely low [37] . In the synovium, RF B cells produce RFs with multiple replacement mutations in their variable regions, and many undergo class switching and affinity maturation. This indicates an antigen and T cell driven process [38, 39] . CD40L expressing, activated T cells [31] can, upon binding with CD40 on B cells, induce proliferation, antibody production and isotype switch. CD40L is upregulated on T cells after activation by DCs, and this suggests that recently primed T cells are recruited for B cell help and affinity maturation, in a similar mechanism as occurs in the lymph node. The crucial role of CD40 signaling for RF production has been demonstrated in RF transgenic mice that lack mature T and B cells but have rearranged RF B cells. Anti-CD40 antibody could stimulate RF production as efficiently as T cells in these mice. Deletion of RF B cells by human IgG could also be blocked using anti-CD40 antibody [40 • ]. The importance of CD40 signaling in autoantibody production has also been shown by studies in lupus-prone mice where IgG autoantibodies are reduced after blocking CD40 signaling [41] . Synoviocytes can, in addition, support terminal B cell survival and differentiation, even though the involvement of CD40 in these interactions is not clear [42] . T cell signaling through CD40/CD40L appears to be a major factor in the inhibition of apoptosis of high affinity RF B cells, as well as in the production of RF.
Monocytes as APCs
Most synovial macrophages are located in the lining layer, where they are thought to be major contributors to cytokine production and joint destruction. The synovial macrophages are in an activated stage and have an increased expression of HLA-DR, which enhances their antigen presenting capacity [43] . Synovial macrophages, like DCs and B cells, express the costimulatory molecule CD86 [44] . Synovial macrophages have also been shown to express STAT 4, which further demonstrates their activated stage and also indicates a role of these cells in IL-12 secretion and activation/polarization of Th1 cells [45] . IFNγ is known to be a potent activator of macrophages, but the level of IFNγ in the synovium is very low [46] . It has therefore been argued that granulocyte macrophage-colony stimulating factor, which performs many similar roles to IFNγ, may play a more important role in the activation of macrophages. Synovial T cells have also been shown to activate macrophages upon cell-cell interaction where CD40L interaction is important to induce cytotoxicity, HLA-DR expression and cytokine production. Synovial monocytes are shown to be more efficient APCs than their counterparts isolated from peripheral blood [47] . Even so, macrophages may not be important in antigen presentation, as they are mainly located in the synovial lining that is distant from the T cell rich area. However, some macrophages are located in the perivascular area, and these might have specialized APC functions compared with the macrophages in the lining layer, as the former express nuclear RelB and CD68 [48] .
Conclusion
There is considerable evidence indicating an ongoing aberrant immune response in the synovial tissues of RA patients. This is critically dependent on the activation of T cells, and much of the resulting tissue destruction is a consequence of the resulting pro-inflammatory cytokine production. The clinical importance of these cytokines has been demonstrated by anti-TNFα therapies in rheumatoid arthritis patients, which have been shown to be powerful treatments for the majority of RA patients, although a substantial minority does not respond [49] . An alternative approach to treatment could be to reduce T cell activation by the blocking of upstream events, particularly the costimulatory signaling pathways involved during APC-T cell interaction.
